RT Journal Article SR Electronic T1 A brief report: de novo copy number variants in children with attention deficit hyperactivity disorder JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2019.12.12.19014555 DO 10.1101/2019.12.12.19014555 A1 Joanna Martin A1 Grace Hosking A1 Megan Wadon A1 Sharifah Shameem Agha A1 Kate Langley A1 Elliott Rees A1 Michael J Owen A1 Michael O’Donovan A1 George Kirov A1 Anita Thapar YR 2019 UL http://medrxiv.org/content/early/2019/12/15/2019.12.12.19014555.abstract AB Background Recent case-control genetic studies of attention deficit hyperactivity disorder (ADHD) have implicated common and rare genetic risk alleles, highlighting the polygenic and complex aetiology of this neurodevelopmental disorder. Studies of other neurodevelopmental disorders, such as autism spectrum disorder (ASD), Tourette disorder, developmental delay/intellectual disability, and schizophrenia indicate that identification of specific risk alleles and additional insights into disorder biology can be gained by studying non-inherited de novo variation. In this study, we aimed to identify large de novo copy number variants (CNVs) in children with ADHD.Methods Children with a confirmed diagnosis of ADHD and their parents were genotyped and included in this sample. We used PennCNV to call large (>200kb) CNVs and identified those calls that were present in the proband and absent in both biological parents.Results In 305 parent-offspring trios, we detected 14 de novo CNVs in 13 probands, giving a mutation rate of 4.6% and a per individual rate of 4.3%. This rate is higher than published reports in controls and similar to those observed for ASD, schizophrenia and Tourette disorder. We also identified de novo mutations at 4 genomic loci (15q13.1-13.2 duplication, 16p13.11 duplication, 16p12.2 deletion and 22q11.21 duplication) that have previously been implicated in other neurodevelopmental disorders, two of which (16p13.11 and 22q11.21) have also been implicated in case-control ADHD studies.Conclusions Our study complements ADHD case-control genomic analyses and demonstrates the need for larger parent-offspring trio genetic studies to gain further insights into the complex aetiology of ADHD.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe work was supported by funding from the Wellcome Trust (Grants 079711 and 106047), Medical Research Council Centre (Grant No. MR/L010305/1), Health and Care Research Wales (grant number: 514032), Action Medical Research, and Baily Thomas.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesGenetic data are available via the PGC ADHD consortium. https://www.med.unc.edu/pgc/results-and-downloads/adhd/?choice=Attention+Deficit+Hyperactivity+Disorder+%28ADHD%29